ClinicalTrials.Veeva

Menu

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

N

Naval Military Medical University (Second Military Medical University)

Status and phase

Not yet enrolling
Phase 4

Conditions

Bacteremia
Acute Rejection of Renal Transplant
Viremia

Treatments

Drug: IVIG

Study type

Interventional

Funder types

Other

Identifiers

NCT05799716
CT20230313

Details and patient eligibility

About

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are:

  1. How effective IVIG is in preventing donor-derived infections
  2. Does IVIG has potential immunomodulatory effect on transplanted organs

Full description

Donor-derived infections are defined as any infection present in the donor that is transmitted to one or more recipient. Donor-derived infections can be categorized into two groups: "expected" and "unexpected" infections. Expected transmissions occur when the donor is known to have an infection, as demonstrated by positive serology or nucleic acid test (NAT) result for cytomegalovirus (CMV), Epstein-Barr virus (EBV) or hepatitis B and C, or positive cultures in the donor at the time of donation. Unexpected transmissions may occur despite current screening strategies and are not expected in the donor at the time of organ placement.

Intravenous immunoglobulins (IVIG) are produced by pooling together of serum immunoglobulins from multiple donors, and are known to have powerful immunomodulatory and anti-inflammatory functions in vitro and in vivo. The goal of this study is to figure out the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs.

Enrollment

40 estimated patients

Sex

All

Ages

6 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any person approved as a transplant donor with recipient who has never undergone a previous transplantation
  • Transplant donor must be 6 years old or older
  • They must have provided signed informed consent
  • The donors must be willing to contribute samples of blood

Exclusion criteria

  • Any potential transplant donor who is receiving or have received anti-herpes medication in the past week
  • Any potential transplant donor to a recipient who has received a previous solid organ transplant
  • Any potential transplant donor who is immunosuppressed due to medical disease and/or immunosuppressive or immunomodulating medications
  • Any potential transplant donor who is on corticosteroids

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

40 participants in 2 patient groups

IVIG
Experimental group
Treatment:
Drug: IVIG
Sham
No Intervention group

Trial contacts and locations

0

Loading...

Central trial contact

Jinghui Yang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems